April 11, 2019

Notice Regarding Reorganization of Research,Production, and Technology Bases
Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President &Representative Director: Masayuki Mitsuka; hereinafter, “MTPC”) has decided toreorganize and consolidate its bases in order to strengthen its domestic research,production, and technology functions. Accompanying this reorganization, MTPC
has decided to close the Toda Office (Saitama Prefecture) and the Kashima Office(Osaka City).
MTPC is implementing a range of initiatives for the period covered by the MediumTerm Management Plan 16-20 and the subsequent period to fiscal 2023. These
include reviewing the allocation of management resources, working to optimize
and increase the efficiency of global management systems, and taking steps tostrengthen each of the Company’s functions.
As one part of those initiatives, MTPC is working to aggressively advance open
innovation in drug discovery research. To that end, for a certain period of time
starting in May 2019, the Company will utilize Shonan Health Innovation Park
(hereinafter, “Shonan iPark”) in Kanagawa Prefecture as a research base. In thisway, MTPC will strive to rapidly and actively take on the challenges of newtechnologies, new treatments, and new disease fields. The companies at Shonan
iPark include not only pharmaceutical companies and drug discovery venturecompanies but also companies involved in R&D support services, researchequipment and medical devices, and AI and IoT. Activities to recruit morecompanies are also being implemented. In stages, MTPC will assign approximately
250 research personnel to Shonan iPark, principally from the Frontier/ResearchUnit and the Modality Laboratory of the Yokohama Office and the Toda Office (tobe closed in fiscal 2019). In this way, MTPC will build a human relations networkwith other companies in Shonan iPark and obtain opportunities for collaboration.
By reorganizing the research function, with a special focus on the realization ofdefinitive therapies through genetic drug discovery, MTPC will strive to provide
new drugs and medical treatment services that address intractable diseases andrare diseases, from prevention to complete cures.

1/2

Furthermore, in regard to the production and technology functions, MTPC will takesteps to bolster its production technology capabilities, establish a global-level new
drug supply system, and transition to a flexible, efficient production system that
demonstrates strength in handling changes in the operating environment. To thatend, MTPC will consolidate the production and technology functions into two bases— the Onoda Office (Yamaguchi Prefecture) and the Yoshitomi Office (FukuokaPrefecture). Specifically, the Kashima Office’s CMC research function will betransferred to the Onoda Office. MTPC will strengthen collaboration between theproduction and CMC research functions, build an integrated manufacturing &technological development platform and utilize the Onoda Office as a technology
base that addresses new technologies and modalities. The pharmaceutical mass
production function will be consolidated into the Yoshitomi Office. Accordingly,
MTPC has decided to close the Kashima Office in fiscal 2021.

Mitsubishi Tanabe Pharma Corporation
Corporate Communications Department
Media contacts: TEL:+81 6 6205 5119
Investor contacts: TEL:+81 6 6205 5110

2/2